NCT06697561 is a NA clinical trial of patient education program in Scleroderma, Systemic, sponsored by Wen-Shao Lin.

Who is sponsoring NCT06697561?

NCT06697561 is sponsored by Wen-Shao Lin.

What drugs are being tested in NCT06697561?

Interventions in NCT06697561: patient education program.

What condition does NCT06697561 study?

NCT06697561 studies Scleroderma, Systemic.

Is NCT06697561 still recruiting?

NCT06697561 is currently active, enrolled. Last updated 20 November 2024.

Last reviewed 2024-11-20 · How we verify

NCT06697561

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development and Evaluation of an Evidence-based Education Program for People With Hand Dysfunction in Scleroderma

Active, enrolled NA Last updated 20 November 2024

What this trial tests

NA trial testing patient education program in Scleroderma, Systemic in 40 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 July 2024

Primary endpoint
30 June 2025

31 July 2025

Quick facts

Lead sponsor	Wen-Shao Lin
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	40
Start date	30 July 2024
Primary completion	30 June 2025
Estimated completion	31 July 2025
Sites	1 location across Taiwan

Drugs / interventions tested

patient education program

Conditions studied

Scleroderma, Systemic — all drugs for Scleroderma, Systemic →

Sponsor

Wen-Shao Lin

Who can join

18 and older, any sex, with Scleroderma, Systemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to develop an evidence-based educational program for scleroderma patients with hand dysfunction. The program includes a self-care handbook and multimedia video resources. The study aims to answer: Does the intervention improve hand function in the experimental group compared to the control group? Does the intervention improve self-care knowledge of hand dysfunction? Does the intervention improve overall health? Participants will receive an 8-week program, while the control group receives usual care. Outcome measures include hand function, overall health, and self-care knowledge.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Scleroderma, Systemic

Currently open trials in the same condition.

NCT06256575 — Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis · NA · recruiting
NCT05878717 — A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease · Phase 2, PHASE3 · recruiting
NCT07345052 — Western Sweden Systemic Sclerosis Project · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06697561 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wen-Shao Lin
Last refreshed: 20 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06697561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing